Jaime Belkind-Gerson
Concepts (345)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Enteric Nervous System | 12 | 2024 | 22 | 4.450 |
Why?
| | Neural Stem Cells | 9 | 2020 | 157 | 2.790 |
Why?
| | Constipation | 10 | 2025 | 94 | 2.470 |
Why?
| | Neurogenesis | 8 | 2024 | 149 | 2.230 |
Why?
| | Anal Canal | 8 | 2025 | 97 | 1.550 |
Why?
| | Manometry | 8 | 2020 | 95 | 1.540 |
Why?
| | Defecation | 3 | 2019 | 19 | 1.460 |
Why?
| | Rectum | 5 | 2020 | 185 | 1.350 |
Why?
| | Myelin Proteolipid Protein | 2 | 2022 | 62 | 1.320 |
Why?
| | Gastrointestinal Motility | 4 | 2022 | 27 | 1.300 |
Why?
| | Gastrointestinal Diseases | 5 | 2025 | 210 | 1.260 |
Why?
| | Gastroenterology | 6 | 2021 | 181 | 1.190 |
Why?
| | Neuroglia | 8 | 2022 | 172 | 1.160 |
Why?
| | Diarrhea | 16 | 2014 | 183 | 1.080 |
Why?
| | Hirschsprung Disease | 6 | 2017 | 87 | 1.010 |
Why?
| | Neurons | 8 | 2022 | 1613 | 0.980 |
Why?
| | Colitis | 3 | 2019 | 265 | 0.950 |
Why?
| | Botulinum Toxins, Type A | 3 | 2025 | 51 | 0.940 |
Why?
| | Travel | 15 | 2014 | 130 | 0.930 |
Why?
| | Intestinal Mucosa | 4 | 2022 | 621 | 0.910 |
Why?
| | Deglutition | 1 | 2024 | 72 | 0.840 |
Why?
| | Stem Cell Transplantation | 5 | 2017 | 177 | 0.770 |
Why?
| | Neuromuscular Agents | 2 | 2025 | 39 | 0.770 |
Why?
| | Endoscopy, Gastrointestinal | 1 | 2024 | 227 | 0.740 |
Why?
| | Schwann Cells | 1 | 2020 | 34 | 0.690 |
Why?
| | Colon | 5 | 2020 | 280 | 0.690 |
Why?
| | Esophageal Achalasia | 1 | 2020 | 30 | 0.670 |
Why?
| | SOXB1 Transcription Factors | 2 | 2017 | 61 | 0.640 |
Why?
| | Pelvic Floor | 1 | 2019 | 22 | 0.620 |
Why?
| | Ataxia | 1 | 2019 | 45 | 0.620 |
Why?
| | Serotonin 5-HT4 Receptor Agonists | 2 | 2016 | 2 | 0.610 |
Why?
| | Pediatrics | 2 | 2023 | 1123 | 0.540 |
Why?
| | Gastrointestinal Transit | 2 | 2013 | 6 | 0.520 |
Why?
| | Child | 25 | 2025 | 22037 | 0.520 |
Why?
| | Escherichia coli Infections | 7 | 2011 | 111 | 0.500 |
Why?
| | Cell Transplantation | 1 | 2016 | 37 | 0.500 |
Why?
| | Pressure | 2 | 2014 | 244 | 0.500 |
Why?
| | Physical Therapy Modalities | 1 | 2019 | 309 | 0.490 |
Why?
| | Child Nutritional Physiological Phenomena | 2 | 2008 | 107 | 0.490 |
Why?
| | Brain | 6 | 2025 | 2831 | 0.480 |
Why?
| | Nerve Regeneration | 3 | 2019 | 62 | 0.470 |
Why?
| | Anesthetics, Intravenous | 1 | 2014 | 47 | 0.430 |
Why?
| | Reflex | 1 | 2014 | 69 | 0.430 |
Why?
| | Proteolipids | 2 | 2024 | 31 | 0.420 |
Why?
| | Propofol | 1 | 2014 | 73 | 0.420 |
Why?
| | Colonoscopy | 1 | 2015 | 247 | 0.400 |
Why?
| | Cell Proliferation | 6 | 2019 | 2482 | 0.360 |
Why?
| | Mice | 13 | 2024 | 17843 | 0.360 |
Why?
| | Animals | 22 | 2024 | 37011 | 0.350 |
Why?
| | Humans | 53 | 2025 | 137514 | 0.340 |
Why?
| | Adult Stem Cells | 2 | 2007 | 41 | 0.330 |
Why?
| | Intestines | 2 | 2019 | 359 | 0.320 |
Why?
| | Mexico | 15 | 2014 | 220 | 0.320 |
Why?
| | Mice, Transgenic | 4 | 2017 | 2182 | 0.320 |
Why?
| | Adolescent | 24 | 2025 | 21555 | 0.320 |
Why?
| | Intermediate Filament Proteins | 2 | 2012 | 57 | 0.310 |
Why?
| | Child, Preschool | 11 | 2025 | 11097 | 0.310 |
Why?
| | Gastrointestinal Tract | 3 | 2023 | 194 | 0.300 |
Why?
| | Child Nutrition Disorders | 1 | 2008 | 20 | 0.300 |
Why?
| | Fecal Incontinence | 2 | 2020 | 86 | 0.290 |
Why?
| | Nutritional Requirements | 1 | 2008 | 77 | 0.290 |
Why?
| | Nervous System | 1 | 2008 | 69 | 0.290 |
Why?
| | Fatty Acids, Unsaturated | 1 | 2008 | 98 | 0.280 |
Why?
| | Nestin | 3 | 2015 | 19 | 0.270 |
Why?
| | Milk, Human | 1 | 2008 | 158 | 0.260 |
Why?
| | Infant Nutritional Physiological Phenomena | 1 | 2008 | 144 | 0.260 |
Why?
| | Inflammation | 2 | 2017 | 2837 | 0.260 |
Why?
| | Nerve Tissue Proteins | 3 | 2013 | 599 | 0.260 |
Why?
| | Dextran Sulfate | 2 | 2017 | 83 | 0.250 |
Why?
| | Escherichia coli | 5 | 2014 | 815 | 0.250 |
Why?
| | Chick Embryo | 3 | 2017 | 131 | 0.250 |
Why?
| | Stem Cells | 3 | 2007 | 589 | 0.250 |
Why?
| | Myocytes, Smooth Muscle | 2 | 2007 | 260 | 0.240 |
Why?
| | Irritable Bowel Syndrome | 2 | 2017 | 29 | 0.240 |
Why?
| | Male | 31 | 2025 | 67718 | 0.240 |
Why?
| | Intestine, Small | 2 | 2021 | 155 | 0.240 |
Why?
| | Retrospective Studies | 9 | 2020 | 15628 | 0.240 |
Why?
| | Female | 32 | 2025 | 73162 | 0.240 |
Why?
| | Child Welfare | 1 | 2007 | 218 | 0.240 |
Why?
| | Infant | 8 | 2020 | 9467 | 0.230 |
Why?
| | Tensins | 1 | 2024 | 5 | 0.220 |
Why?
| | Esophagus | 2 | 2024 | 255 | 0.220 |
Why?
| | Spinal Cord Injuries | 1 | 2007 | 211 | 0.220 |
Why?
| | Ultrasonography, Interventional | 1 | 2025 | 142 | 0.220 |
Why?
| | North America | 3 | 2021 | 313 | 0.220 |
Why?
| | Endosonography | 1 | 2025 | 156 | 0.210 |
Why?
| | Pancreatic Diseases | 1 | 2004 | 72 | 0.210 |
Why?
| | Mice, Inbred C57BL | 6 | 2017 | 5792 | 0.210 |
Why?
| | Neuronal Plasticity | 1 | 2006 | 291 | 0.210 |
Why?
| | Capsule Endoscopy | 2 | 2013 | 18 | 0.210 |
Why?
| | Tamoxifen | 1 | 2024 | 202 | 0.200 |
Why?
| | Infant, Newborn | 7 | 2020 | 6059 | 0.200 |
Why?
| | Nervous System Diseases | 1 | 2006 | 265 | 0.200 |
Why?
| | Cell Culture Techniques | 2 | 2012 | 363 | 0.200 |
Why?
| | Endoscopy, Digestive System | 1 | 2024 | 136 | 0.200 |
Why?
| | Toxoplasma | 2 | 2013 | 41 | 0.190 |
Why?
| | Clinical Competence | 2 | 2021 | 1093 | 0.190 |
Why?
| | Injections | 2 | 2025 | 182 | 0.190 |
Why?
| | Antibodies, Bacterial | 3 | 2010 | 146 | 0.190 |
Why?
| | Vitamin K Deficiency Bleeding | 1 | 2002 | 4 | 0.190 |
Why?
| | Chronic Disease | 4 | 2022 | 1790 | 0.190 |
Why?
| | Isoamylase | 1 | 2001 | 1 | 0.180 |
Why?
| | Cells, Cultured | 6 | 2017 | 4206 | 0.180 |
Why?
| | Treatment Outcome | 8 | 2025 | 10821 | 0.180 |
Why?
| | Botulinum Toxins | 1 | 2022 | 43 | 0.180 |
Why?
| | Trypsin | 1 | 2001 | 77 | 0.180 |
Why?
| | Adult | 20 | 2021 | 37821 | 0.180 |
Why?
| | Polymorphism, Single Nucleotide | 4 | 2011 | 2193 | 0.180 |
Why?
| | Helicobacter Infections | 1 | 2001 | 32 | 0.180 |
Why?
| | Helicobacter pylori | 1 | 2001 | 42 | 0.170 |
Why?
| | Barium Sulfate | 1 | 2020 | 15 | 0.170 |
Why?
| | Barium | 1 | 2020 | 28 | 0.170 |
Why?
| | Cell Differentiation | 5 | 2014 | 1979 | 0.170 |
Why?
| | Astrocytes | 2 | 2013 | 210 | 0.170 |
Why?
| | Enema | 1 | 2020 | 47 | 0.170 |
Why?
| | Societies, Medical | 2 | 2021 | 820 | 0.170 |
Why?
| | Cachexia | 1 | 2001 | 71 | 0.170 |
Why?
| | Disease Models, Animal | 5 | 2017 | 4295 | 0.170 |
Why?
| | Muscle Spasticity | 1 | 2020 | 61 | 0.160 |
Why?
| | Abnormalities, Multiple | 1 | 2001 | 189 | 0.160 |
Why?
| | Escherichia coli Proteins | 4 | 2008 | 195 | 0.160 |
Why?
| | Anorectal Malformations | 1 | 2020 | 112 | 0.150 |
Why?
| | Pancreas | 1 | 2001 | 328 | 0.150 |
Why?
| | Bone and Bones | 1 | 2001 | 317 | 0.150 |
Why?
| | Enterotoxins | 2 | 2008 | 87 | 0.150 |
Why?
| | Follow-Up Studies | 4 | 2019 | 5139 | 0.140 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 3 | 2012 | 974 | 0.140 |
Why?
| | Bacterial Toxins | 2 | 2008 | 105 | 0.140 |
Why?
| | Mice, Knockout | 2 | 2022 | 3020 | 0.140 |
Why?
| | S100 Calcium Binding Protein beta Subunit | 1 | 2017 | 8 | 0.140 |
Why?
| | Citrobacter rodentium | 1 | 2017 | 7 | 0.140 |
Why?
| | Antidepressive Agents, Tricyclic | 1 | 2017 | 30 | 0.140 |
Why?
| | Submucous Plexus | 1 | 2017 | 2 | 0.140 |
Why?
| | Myenteric Plexus | 1 | 2017 | 4 | 0.140 |
Why?
| | Intestine, Large | 1 | 2017 | 13 | 0.130 |
Why?
| | Immunohistochemistry | 3 | 2015 | 1740 | 0.130 |
Why?
| | Curriculum | 2 | 2021 | 980 | 0.130 |
Why?
| | Polymerase Chain Reaction | 6 | 2011 | 1061 | 0.130 |
Why?
| | Radionuclide Imaging | 2 | 2013 | 119 | 0.130 |
Why?
| | Stem Cell Niche | 1 | 2017 | 54 | 0.130 |
Why?
| | Intestinal Pseudo-Obstruction | 1 | 2016 | 9 | 0.130 |
Why?
| | Laxatives | 1 | 2016 | 19 | 0.130 |
Why?
| | Poloxamer | 1 | 2016 | 13 | 0.130 |
Why?
| | Radiation Injuries, Experimental | 1 | 2016 | 22 | 0.120 |
Why?
| | Abdominal Pain | 1 | 2017 | 146 | 0.120 |
Why?
| | Virulence Factors | 2 | 2008 | 167 | 0.120 |
Why?
| | Receptor, Endothelin B | 1 | 2015 | 50 | 0.120 |
Why?
| | Fellowships and Scholarships | 1 | 2019 | 306 | 0.120 |
Why?
| | Cell- and Tissue-Based Therapy | 1 | 2016 | 82 | 0.120 |
Why?
| | Integrin alpha2 | 1 | 2015 | 3 | 0.120 |
Why?
| | Deoxyuridine | 1 | 2015 | 6 | 0.120 |
Why?
| | Norovirus | 2 | 2005 | 26 | 0.120 |
Why?
| | Mice, 129 Strain | 1 | 2015 | 88 | 0.120 |
Why?
| | Delayed-Action Preparations | 1 | 2016 | 180 | 0.120 |
Why?
| | Cell Transdifferentiation | 1 | 2015 | 31 | 0.120 |
Why?
| | Sulfonamides | 2 | 2016 | 513 | 0.110 |
Why?
| | Providencia | 1 | 2014 | 1 | 0.110 |
Why?
| | Students, Medical | 1 | 2019 | 341 | 0.110 |
Why?
| | Cystic Fibrosis | 1 | 2004 | 1105 | 0.110 |
Why?
| | United States | 11 | 2021 | 14696 | 0.110 |
Why?
| | Gastrointestinal Microbiome | 1 | 2021 | 696 | 0.110 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 5 | 2011 | 849 | 0.100 |
Why?
| | Anesthesia, General | 1 | 2014 | 73 | 0.100 |
Why?
| | Defecography | 1 | 2013 | 3 | 0.100 |
Why?
| | Gastroparesis | 1 | 2013 | 9 | 0.100 |
Why?
| | Gastric Emptying | 1 | 2013 | 38 | 0.100 |
Why?
| | Protozoan Proteins | 1 | 2013 | 82 | 0.100 |
Why?
| | Research | 2 | 2007 | 446 | 0.100 |
Why?
| | Cell Survival | 1 | 2016 | 1122 | 0.100 |
Why?
| | Biopsy | 1 | 2016 | 1132 | 0.100 |
Why?
| | Intestinal Obstruction | 1 | 2013 | 50 | 0.100 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2013 | 188 | 0.100 |
Why?
| | Cell Movement | 1 | 2017 | 972 | 0.100 |
Why?
| | Fluorescent Antibody Technique | 1 | 2012 | 386 | 0.090 |
Why?
| | Young Adult | 7 | 2020 | 13243 | 0.090 |
Why?
| | Campylobacter jejuni | 1 | 2010 | 11 | 0.090 |
Why?
| | Lipopolysaccharide Receptors | 1 | 2011 | 86 | 0.090 |
Why?
| | Campylobacter Infections | 1 | 2010 | 16 | 0.090 |
Why?
| | Brain Injuries | 1 | 2016 | 493 | 0.090 |
Why?
| | Gene Expression Regulation | 2 | 2017 | 2615 | 0.080 |
Why?
| | Immunoglobulins | 1 | 2010 | 171 | 0.080 |
Why?
| | Mice, Inbred BALB C | 3 | 2013 | 1271 | 0.080 |
Why?
| | Osteoprotegerin | 1 | 2009 | 24 | 0.080 |
Why?
| | Dichlorodiphenyl Dichloroethylene | 1 | 2008 | 4 | 0.080 |
Why?
| | Escherichia coli Vaccines | 1 | 2008 | 4 | 0.070 |
Why?
| | Enterotoxigenic Escherichia coli | 1 | 2008 | 5 | 0.070 |
Why?
| | Cryptosporidiosis | 1 | 2008 | 21 | 0.070 |
Why?
| | Practice Guidelines as Topic | 2 | 2008 | 1580 | 0.070 |
Why?
| | Occult Blood | 1 | 2008 | 34 | 0.070 |
Why?
| | Cell Lineage | 2 | 2014 | 346 | 0.070 |
Why?
| | Quadriplegia | 1 | 2007 | 12 | 0.070 |
Why?
| | Infant Formula | 1 | 2008 | 75 | 0.070 |
Why?
| | Rifamycins | 1 | 2007 | 5 | 0.070 |
Why?
| | Loperamide | 1 | 2007 | 11 | 0.070 |
Why?
| | Lactoferrin | 1 | 2007 | 31 | 0.070 |
Why?
| | Risk Factors | 6 | 2025 | 10356 | 0.070 |
Why?
| | Maternal Exposure | 1 | 2008 | 188 | 0.070 |
Why?
| | Nerve Growth Factors | 1 | 2007 | 80 | 0.060 |
Why?
| | Promoter Regions, Genetic | 1 | 2011 | 1255 | 0.060 |
Why?
| | Digestive System Physiological Phenomena | 1 | 2006 | 4 | 0.060 |
Why?
| | Interleukin-10 | 1 | 2008 | 302 | 0.060 |
Why?
| | Intestinal Diseases | 1 | 2006 | 41 | 0.060 |
Why?
| | Neural Crest | 1 | 2007 | 116 | 0.060 |
Why?
| | Pregnancy | 3 | 2025 | 6745 | 0.060 |
Why?
| | Caliciviridae Infections | 1 | 2005 | 19 | 0.060 |
Why?
| | Feces | 4 | 2011 | 479 | 0.060 |
Why?
| | Liver Diseases | 1 | 2008 | 313 | 0.060 |
Why?
| | Global Health | 1 | 2008 | 386 | 0.060 |
Why?
| | Spinal Cord | 1 | 2007 | 369 | 0.060 |
Why?
| | Antiparasitic Agents | 1 | 2004 | 3 | 0.060 |
Why?
| | Albendazole | 1 | 2004 | 5 | 0.060 |
Why?
| | Intestinal Diseases, Parasitic | 1 | 2004 | 11 | 0.060 |
Why?
| | Anthelmintics | 1 | 2004 | 11 | 0.060 |
Why?
| | Developing Countries | 1 | 2006 | 305 | 0.060 |
Why?
| | Gastroesophageal Reflux | 1 | 2007 | 235 | 0.060 |
Why?
| | Glial Cell Line-Derived Neurotrophic Factor Receptors | 1 | 2004 | 2 | 0.050 |
Why?
| | Anti-Infective Agents | 1 | 2007 | 256 | 0.050 |
Why?
| | Bromodeoxyuridine | 1 | 2004 | 80 | 0.050 |
Why?
| | Biofilms | 1 | 2006 | 262 | 0.050 |
Why?
| | Thiazoles | 1 | 2004 | 123 | 0.050 |
Why?
| | Students | 2 | 2008 | 625 | 0.050 |
Why?
| | Coloring Agents | 1 | 2004 | 86 | 0.050 |
Why?
| | Pilot Projects | 2 | 2025 | 1703 | 0.050 |
Why?
| | International Cooperation | 1 | 2004 | 198 | 0.050 |
Why?
| | Glial Fibrillary Acidic Protein | 2 | 2014 | 100 | 0.050 |
Why?
| | Embryo, Nonmammalian | 1 | 2003 | 167 | 0.050 |
Why?
| | Cohort Studies | 4 | 2011 | 5730 | 0.050 |
Why?
| | Evidence-Based Medicine | 1 | 2007 | 746 | 0.050 |
Why?
| | Embryo, Mammalian | 1 | 2003 | 232 | 0.050 |
Why?
| | Middle Aged | 9 | 2010 | 33355 | 0.050 |
Why?
| | Genetic Predisposition to Disease | 2 | 2009 | 2420 | 0.050 |
Why?
| | Central Nervous System | 1 | 2004 | 261 | 0.050 |
Why?
| | Nutrition Disorders | 1 | 2001 | 23 | 0.050 |
Why?
| | Dwarfism | 1 | 2001 | 17 | 0.050 |
Why?
| | Leukemia, Myeloid | 1 | 2001 | 45 | 0.040 |
Why?
| | Sensitivity and Specificity | 3 | 2013 | 1950 | 0.040 |
Why?
| | Neutropenia | 1 | 2001 | 146 | 0.040 |
Why?
| | Fatal Outcome | 1 | 2001 | 305 | 0.040 |
Why?
| | Immunoglobulin G | 3 | 2010 | 886 | 0.040 |
Why?
| | Syndrome | 1 | 2001 | 359 | 0.040 |
Why?
| | Biomarkers | 2 | 2014 | 4172 | 0.040 |
Why?
| | Hematopoietic Stem Cells | 1 | 2003 | 398 | 0.040 |
Why?
| | Bone Marrow | 1 | 2001 | 286 | 0.040 |
Why?
| | Temperature | 2 | 2016 | 680 | 0.040 |
Why?
| | Calcinosis | 1 | 2001 | 235 | 0.040 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2004 | 784 | 0.040 |
Why?
| | Shock, Septic | 1 | 2001 | 221 | 0.040 |
Why?
| | Liver Cirrhosis | 1 | 2001 | 316 | 0.040 |
Why?
| | Rats | 1 | 2007 | 5676 | 0.040 |
Why?
| | Canada | 2 | 2011 | 421 | 0.040 |
Why?
| | Acute Disease | 1 | 2001 | 1008 | 0.040 |
Why?
| | Age Factors | 2 | 2008 | 3301 | 0.040 |
Why?
| | Celiac Disease | 1 | 2001 | 293 | 0.040 |
Why?
| | Poverty | 1 | 2001 | 520 | 0.030 |
Why?
| | Surveys and Questionnaires | 2 | 2019 | 5772 | 0.030 |
Why?
| | Virulence | 2 | 2008 | 266 | 0.030 |
Why?
| | Socioeconomic Factors | 1 | 2001 | 1286 | 0.030 |
Why?
| | Transplantation, Isogeneic | 1 | 2015 | 17 | 0.030 |
Why?
| | Spheroids, Cellular | 1 | 2017 | 76 | 0.030 |
Why?
| | Risk Assessment | 3 | 2014 | 3439 | 0.030 |
Why?
| | RNA, Messenger | 1 | 2004 | 2838 | 0.030 |
Why?
| | Prognosis | 1 | 2004 | 4031 | 0.030 |
Why?
| | Physician's Role | 1 | 2017 | 206 | 0.030 |
Why?
| | Guatemala | 2 | 2008 | 333 | 0.030 |
Why?
| | Hydrogel, Polyethylene Glycol Dimethacrylate | 1 | 2016 | 76 | 0.030 |
Why?
| | Reference Values | 2 | 2007 | 821 | 0.030 |
Why?
| | Analysis of Variance | 2 | 2009 | 1324 | 0.030 |
Why?
| | Calbindin 2 | 1 | 2014 | 8 | 0.030 |
Why?
| | Peripheral Nervous System Diseases | 1 | 2016 | 129 | 0.030 |
Why?
| | Synaptophysin | 1 | 2014 | 14 | 0.030 |
Why?
| | CD57 Antigens | 1 | 2014 | 18 | 0.030 |
Why?
| | S100 Proteins | 1 | 2014 | 37 | 0.030 |
Why?
| | CD56 Antigen | 1 | 2014 | 36 | 0.030 |
Why?
| | Education, Medical, Graduate | 1 | 2019 | 481 | 0.030 |
Why?
| | Severity of Illness Index | 2 | 2016 | 2838 | 0.030 |
Why?
| | Cell Shape | 1 | 2014 | 58 | 0.030 |
Why?
| | Time Factors | 3 | 2014 | 6817 | 0.030 |
Why?
| | Liposomes | 1 | 2016 | 221 | 0.030 |
Why?
| | Guidelines as Topic | 1 | 2016 | 277 | 0.030 |
Why?
| | Case-Control Studies | 2 | 2014 | 3546 | 0.030 |
Why?
| | Genes, bcl-2 | 1 | 2013 | 21 | 0.030 |
Why?
| | Specific Pathogen-Free Organisms | 1 | 2013 | 60 | 0.030 |
Why?
| | Tubulin | 1 | 2014 | 141 | 0.030 |
Why?
| | Inhibitor of Apoptosis Proteins | 1 | 2013 | 50 | 0.030 |
Why?
| | Symptom Assessment | 1 | 2014 | 126 | 0.030 |
Why?
| | Cell Line | 2 | 2009 | 2852 | 0.020 |
Why?
| | Poly(ADP-ribose) Polymerases | 1 | 2013 | 99 | 0.020 |
Why?
| | Double-Blind Method | 2 | 2008 | 1987 | 0.020 |
Why?
| | Poly (ADP-Ribose) Polymerase-1 | 1 | 2013 | 51 | 0.020 |
Why?
| | Sex Factors | 2 | 2008 | 2074 | 0.020 |
Why?
| | Age of Onset | 1 | 2014 | 522 | 0.020 |
Why?
| | Caspases | 1 | 2013 | 247 | 0.020 |
Why?
| | Logistic Models | 1 | 2017 | 2064 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2013 | 234 | 0.020 |
Why?
| | Cisplatin | 1 | 2013 | 318 | 0.020 |
Why?
| | Nucleic Acid Hybridization | 1 | 2011 | 190 | 0.020 |
Why?
| | Aged | 2 | 2007 | 23798 | 0.020 |
Why?
| | Tumor Suppressor Proteins | 1 | 2013 | 328 | 0.020 |
Why?
| | Animals, Newborn | 1 | 2013 | 845 | 0.020 |
Why?
| | Nanoparticles | 1 | 2016 | 484 | 0.020 |
Why?
| | Thromboxane B2 | 1 | 1989 | 26 | 0.020 |
Why?
| | Repressor Proteins | 1 | 2013 | 425 | 0.020 |
Why?
| | Pancreas Transplantation | 1 | 1989 | 75 | 0.020 |
Why?
| | Microbial Sensitivity Tests | 1 | 2010 | 362 | 0.020 |
Why?
| | Immunoglobulin A | 1 | 2010 | 210 | 0.020 |
Why?
| | Disease Susceptibility | 1 | 2011 | 344 | 0.020 |
Why?
| | Immunoglobulin M | 1 | 2010 | 288 | 0.020 |
Why?
| | Endocrine System | 1 | 2008 | 20 | 0.020 |
Why?
| | Cryptosporidium | 1 | 2008 | 13 | 0.020 |
Why?
| | Practice Patterns, Physicians' | 1 | 2017 | 1312 | 0.020 |
Why?
| | Serologic Tests | 1 | 2008 | 54 | 0.020 |
Why?
| | Administration, Cutaneous | 1 | 2008 | 128 | 0.020 |
Why?
| | Androgen Antagonists | 1 | 2008 | 82 | 0.020 |
Why?
| | Bacteriological Techniques | 1 | 2008 | 71 | 0.020 |
Why?
| | Pregnancy Trimester, First | 1 | 2008 | 142 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2019 | 5427 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2009 | 533 | 0.020 |
Why?
| | Bacterial Adhesion | 1 | 2008 | 99 | 0.020 |
Why?
| | Prospective Studies | 2 | 2011 | 7598 | 0.020 |
Why?
| | Specimen Handling | 1 | 2008 | 178 | 0.020 |
Why?
| | DNA, Bacterial | 1 | 2008 | 336 | 0.020 |
Why?
| | Probability | 1 | 2007 | 311 | 0.020 |
Why?
| | Regression Analysis | 1 | 2008 | 1029 | 0.020 |
Why?
| | Odds Ratio | 1 | 2008 | 1063 | 0.020 |
Why?
| | Graft Rejection | 1 | 1989 | 623 | 0.010 |
Why?
| | Seasons | 1 | 2008 | 546 | 0.010 |
Why?
| | Blotting, Southern | 1 | 2005 | 72 | 0.010 |
Why?
| | Drug Administration Schedule | 1 | 2007 | 784 | 0.010 |
Why?
| | Nitro Compounds | 1 | 2004 | 6 | 0.010 |
Why?
| | Linear Models | 1 | 2007 | 851 | 0.010 |
Why?
| | Gene Expression Regulation, Bacterial | 1 | 2006 | 328 | 0.010 |
Why?
| | Trans-Activators | 1 | 2006 | 399 | 0.010 |
Why?
| | Drug Therapy, Combination | 1 | 2007 | 1060 | 0.010 |
Why?
| | Apoptosis | 1 | 2013 | 2557 | 0.010 |
Why?
| | Multivariate Analysis | 1 | 2007 | 1524 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2007 | 2066 | 0.010 |
Why?
| | Administration, Oral | 1 | 2004 | 814 | 0.010 |
Why?
| | Phylogeny | 1 | 2005 | 898 | 0.010 |
Why?
| | Antineoplastic Agents | 1 | 2013 | 2145 | 0.010 |
Why?
| | Incidence | 1 | 2007 | 2792 | 0.010 |
Why?
| | Genotype | 1 | 2005 | 1920 | 0.010 |
Why?
| | Dogs | 1 | 1989 | 411 | 0.000 |
Why?
| | Glucose Tolerance Test | 1 | 1989 | 361 | 0.000 |
Why?
| | Diabetes Mellitus, Experimental | 1 | 1989 | 194 | 0.000 |
Why?
| | Blood Glucose | 1 | 1989 | 2183 | 0.000 |
Why?
|
|
Belkind-Gerson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|